A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Assess the Efficacy and Safety of IBI362 in Chinese Subjects With Moderate-to-Severe Obstructive Sleep Apnea and BMI≥28 kg/m2 (GLORY-OSA)
Latest Information Update: 07 Jul 2025
At a glance
- Drugs Mazdutide (Primary)
- Indications Sleep apnoea syndrome
- Focus Registrational; Therapeutic Use
- Acronyms GLORY-OSA
- Sponsors Innovent Biologics
Most Recent Events
- 15 Jun 2025 Status changed from not yet recruiting to recruiting, according to Innovent Biologics, Inc media release.
- 15 Jun 2025 According to Innovent Biologics, Inc media release, first participant has been successfully dosed in this study.
- 22 Apr 2025 New trial record